title: Histo-blood group A/B versus H status of human carcinoma cells as correlated with haptotactic cell motility: approach with A and B gene transfection.
abstract: In a search for the molecular basis of ABH status of tumors as correlated with malignancy, we studied various malignancy-related phenotypes of high H/Le(y)-expressing tumor cell lines in comparison with phenotypes of the same lines transfected with histo-blood group A or B genes. A and B gene transfectants, prepared independently from different H-active parental cells, showed A or B activity and abolition of H activity. All A and B gene transfectants, regardless of source, were characterized by significantly reduced Matrigel-dependent haptotactic motility. The level of haptotaxis of all transfectants was similar to that of parental cells in the presence of antibodies against human integrin subunits alpha3, alpha6, or beta1. These subunits showed high expression of A or B epitope in the A and B gene transfectants. Enhancement versus reduction of malignancy, associated with deletion versus induction of A/B epitopes, may be due in part to enhanced haptotaxis sustained by alpha3, alpha6, and beta1 integrin receptors, the activities of which are regulated by H or A/B glycosylation. These phenotypic changes provide a rationale for the deletion of A and B epitopes as one criterion defining human tumor malignancy.
authors.affiliation: Department of Pathobiology, University of Washington, Seattle 98122, USA.
authors.forename: D
authors.initials: D
authors.lastname: Ichikawa
authors.forename: K
authors.initials: K
authors.lastname: Handa
authors.forename: D A
authors.initials: DA
authors.lastname: Withers
authors.forename: S
authors.initials: S
authors.lastname: Hakomori
mesh_terms: D000017:ABO Blood-Group System / Q000235:genetics / Q000502:physiology*; D000911:Antibodies, Monoclonal / Q000494:pharmacology; D000951:Antigens, Neoplasm / Q000235:genetics / Q000502:physiology; D015295:Antigens, Tumor-Associated, Carbohydrate / Q000235:genetics / Q000502:physiology; D002448:Cell Adhesion / Q000187:drug effects; D002465:Cell Movement / Q000187:drug effects / Q000502:physiology; D002999:Clone Cells; D003094:Collagen / Q000502:physiology; D003110:Colonic Neoplasms / Q000097:blood* / Q000235:genetics; D004305:Dose-Response Relationship, Drug; D004338:Drug Combinations; D005109:Extracellular Matrix / Q000502:physiology; D006031:Glycosylation; D006801:Humans; D016023:Integrins / Q000737:chemistry / Q000276:immunology; D007797:Laminin / Q000502:physiology; D007983:Lewis Blood Group Antigens / Q000235:genetics / Q000502:physiology*; D011509:Proteoglycans / Q000502:physiology; D013274:Stomach Neoplasms / Q000097:blood* / Q000235:genetics; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D000017:ABO Blood-Group System; D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D015295:Antigens, Tumor-Associated, Carbohydrate; D004338:Drug Combinations; D016023:Integrins; D007797:Laminin; D007983:Lewis Blood Group Antigens; D011509:Proteoglycans; C059485:matrigel; D003094:Collagen